TY - JOUR
T1 - Study of phanuacokinetic properties of cyclosporiue a after subcutaneous injection in cynomolgus monkey
AU - Kisu, Iori
AU - Kato, Yojiro
AU - Tsuchiya, Hideaki
AU - Kawamoto, Lkuo
AU - Nakagawa, Takahiro
AU - Ogasawara, Kazumasa
AU - Hayakawa, Tomohisa
AU - Yamayoshi, Yasuko
AU - Iketani, OSamu
AU - Mihara, Makoto
AU - Banno, Kouji
AU - Sato, Shin Ichi
AU - Shiina, Takashi
AU - Aoki, Daisuke
N1 - Publisher Copyright:
© 2014 Asian Network for Scientific Information
PY - 2014
Y1 - 2014
N2 - Intramuscular or intravenous injection of Cyclosporine A (CyA) has been performed in some transplantation animal studies, including non-hwnan primates. However, the pharmacokinetics after subcutaneous (s.c.) injection of CyA in cynomolgus monkey has not been reported. In this study CyA was administered subcutaneously in cynomolgus monkeys at three doses and investigated the pharmacokinetics. Six female cynomolgus monkeys were used in the study. CyA was administered once daily at a prescribed time for 7 days in the back of each monkey at doses of 2.5, 5 or 10 mg kg-1in different administration periods. The blood trough level of CyA was measured on consecutive days. On days 0, 1 and 4, the level was measured 2, 4, 6, 8 and 12 h after CyA administration. The mean trough concentrations on day 4 in the 6 animals at doses of 2.5, 5 and 1 0 mg kg_, were 162±56, 356±97 and 652±137 ng mL, respectively, showiug a dose-dependent increase. The average Tmax range at each concentration on days 0 and 4 was 5-11 hand was 5-6 h on day 4 at steady state, with Cmax tending to be not high. The T112 showed general prolongations that were 14-19 h on day 4. Average pharmacokinetic data on day 4 showed dose-dependent and almost linear increases in AUC= which were 9822±3473, 24323±9520 and 43418±12591 ug.hr mL_,at dose of 2.5, 5 and 10 mg kg-', respectively. The pharmacokinetics of CyA after s.c. injection in cynomolgus monkeys showed a slow absorption phase, a Cmax that is not high and a prolouged elimination phase. The linearity of the AUC with dose and the high AUC and trough level in the early days after first administration suggest high bioavailability and sufficient efficacy after s.c. injection.
AB - Intramuscular or intravenous injection of Cyclosporine A (CyA) has been performed in some transplantation animal studies, including non-hwnan primates. However, the pharmacokinetics after subcutaneous (s.c.) injection of CyA in cynomolgus monkey has not been reported. In this study CyA was administered subcutaneously in cynomolgus monkeys at three doses and investigated the pharmacokinetics. Six female cynomolgus monkeys were used in the study. CyA was administered once daily at a prescribed time for 7 days in the back of each monkey at doses of 2.5, 5 or 10 mg kg-1in different administration periods. The blood trough level of CyA was measured on consecutive days. On days 0, 1 and 4, the level was measured 2, 4, 6, 8 and 12 h after CyA administration. The mean trough concentrations on day 4 in the 6 animals at doses of 2.5, 5 and 1 0 mg kg_, were 162±56, 356±97 and 652±137 ng mL, respectively, showiug a dose-dependent increase. The average Tmax range at each concentration on days 0 and 4 was 5-11 hand was 5-6 h on day 4 at steady state, with Cmax tending to be not high. The T112 showed general prolongations that were 14-19 h on day 4. Average pharmacokinetic data on day 4 showed dose-dependent and almost linear increases in AUC= which were 9822±3473, 24323±9520 and 43418±12591 ug.hr mL_,at dose of 2.5, 5 and 10 mg kg-', respectively. The pharmacokinetics of CyA after s.c. injection in cynomolgus monkeys showed a slow absorption phase, a Cmax that is not high and a prolouged elimination phase. The linearity of the AUC with dose and the high AUC and trough level in the early days after first administration suggest high bioavailability and sufficient efficacy after s.c. injection.
KW - Cyclosporine A
KW - Cynomolgus monkey
KW - Pharmacokinetics
KW - Subcutaneous injection
KW - Uterus trans lantation
UR - http://www.scopus.com/inward/record.url?scp=84914106184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84914106184&partnerID=8YFLogxK
U2 - 10.3923/ijp.2014.487.493
DO - 10.3923/ijp.2014.487.493
M3 - Article
AN - SCOPUS:84914106184
SN - 1811-7775
VL - 10
SP - 487
EP - 493
JO - International Journal of Pharmacology
JF - International Journal of Pharmacology
IS - 8
ER -